CIRM has reinvented itself in a new form, CIRM 2.0, under the leadership of its new President Randy Mills. CIRM is almost like a stem cell that has changed into another new kind of stem cell. Us scientists could see the change coming in the “programming” at CIRM in terms of how it was operating as …
The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many …
CIRM 2.0 Should Include Bridges Training Program Read More »
Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a …
What does the future hold for the California Institute for Regenerative Medicine (CIRM), also known as the California Stem Cell Agency? While new CIRM grants should be awarded up until 2017, CIRM is rightly thinking about its future. Californians should be paying attention and thinking ahead too. You might say that since I’m a CIRM …
The Case for CIRM 2.0: Continuing California’s Stem Cell Leadership Read More »
There has been a largely media-fed hullabaloo about the salary for the new Chair of CIRM, the California Institute for Regenerative Medicine, $400,000. Now don’t get me wrong, that sounds like a lot of money to me personally, but we need to put it in perspective and when we do, the salary is reasonable and …
California pays its sports coaches alone more than the entire payroll of CIRM Read More »
CIRM announced two sets of awards today that both should make major impact including its first clinical trial via Geron and $38 million for 27 basic biology studies. First Clinical Trial. Today CIRM awarded $25 million to support Geron’s FDA-approved clinical trial for spinal cord injury. This is CIRM’s first award to a for-profit company …
CIRM funds $25 million for Geron trial, $38 million for basic biology Read More »
CIRM Board Member, Jeff Sheehy, has a wonderful piece in Nature Medicine on why patient advocates play a critical role in decision making on research priorities (hat tip to Amy Adams who first blogged on Sheehy’s piece). Patient advocates bring a unique and valuable perspective to the table. Their role in guiding CIRM research funding …
Why scientists must be advocates too: Jeff Sheehy Read More »